Table 3.
Univariate analysis of prognostic factors correlated with OS.
| Characteristics | mOS (months) | HR (95%CI) | P value |
|---|---|---|---|
| HHLA2 expression | |||
| Low | 14.2 | Reference | |
| High | 52.4 | 0.290 (0.129 to 0.653) | 0.003 |
| Age | |||
| <60 | 17.0 | Reference | |
| ≥60 | 21.5 | 1.125 (0.619 to 2.046) | 0.699 |
| Gender | |||
| Male | 21.0 | Reference | |
| Female | 17.0 | 0.881 (0.512 to 1.518) | 0.649 |
| ECOG PS | |||
| 0 | 22.3 | Reference | |
| 1-2 | 8.3 | 4.467 (2.056 to 9.708) | <0.001 |
| LDH | |||
| Normal | 20.7 | Reference | |
| Elevated | 14.0 | 1.494 (0.769 to 2.902) | 0.236 |
| Subtype | |||
| Cutaneous | 14.4 | Reference | |
| Acral | 29.3 | 0.749 (0.407 to 1.379) | 0.353 |
| Mucosal | 8.9 | 1.716 (0.843 to 3.492) | 0.137 |
| Tumor stage | |||
| Stage III | 19.3 | Reference | |
| Stage IV | 17.9 | 1.903 (0.463 to 7.820) | 0.372 |
| Liver metastasis | |||
| No | 23.9 | Reference | |
| Yes | 4.8 | 3.918 (2.059 to 7.455) | <0.001 |
| Brain metastasis | |||
| No | 20.7 | Reference | |
| Yes | 12.4 | 1.401 (0.599 to 3.280) | 0.437 |
| Line of systematic treatment | |||
| First | 16.4 | Reference | |
| Second | 17.9 | 1.270 (0.705 to 2.288) | 0.426 |
| Type of immunotherapy | |||
| Anti-PD-1/PD-L1/CTLA4 monotherapy | 14.2 | Reference | |
| Anti-PD-1/PD-L1+ Anti-CTLA-4 therapy | 38.2 | 0.328 (0.098 to 1.094) | 0.070 |
| Anti-PD-1/PD-L1+ other therapies | 17.0 | 0.822 (0.472 to 1.433) | 0.490 |
*P values <0.05 in bold are statistically significant.
HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenases; PD-1, programmed cell death protein-1; PD-L1, programmed death 1 ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4.